Cantor Fitzgerald Predicts Kura Oncology FY2026 Earnings

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Kura Oncology in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings per share of ($2.44) for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Kura Oncology's current full-year earnings is ($2.44) per share.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The business had revenue of $14.11 million for the quarter, compared to the consensus estimate of $39.08 million.

Other analysts also recently issued research reports about the company. JMP Securities reaffirmed a "market outperform" rating and issued a $28.00 price objective on shares of Kura Oncology in a research note on Wednesday, June 4th. Wedbush restated an "outperform" rating and issued a $36.00 price target on shares of Kura Oncology in a research report on Tuesday, April 8th. UBS Group decreased their price target on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Kura Oncology in a research note on Monday, April 28th. Finally, Wall Street Zen downgraded shares of Kura Oncology from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Four analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $24.50.

Kura Oncology Price Performance

Shares of Kura Oncology stock traded down $0.22 during trading on Tuesday, reaching $6.44. 1,120,441 shares of the stock traded hands, compared to its average volume of 1,228,264. Kura Oncology has a 52-week low of $5.41 and a 52-week high of $23.48. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The business has a fifty day simple moving average of $6.14 and a two-hundred day simple moving average of $7.52. The company has a market capitalization of $557.54 million, a price-to-earnings ratio of -2.73 and a beta of 0.40.

Hedge Funds Weigh In On Kura Oncology

Several hedge funds have recently added to or reduced their stakes in the company. BVF Inc. IL lifted its stake in Kura Oncology by 202.0% in the first quarter. BVF Inc. IL now owns 7,754,129 shares of the company's stock worth $51,177,000 after purchasing an additional 5,186,660 shares during the last quarter. Armistice Capital LLC raised its holdings in shares of Kura Oncology by 13.3% in the first quarter. Armistice Capital LLC now owns 6,572,000 shares of the company's stock worth $43,375,000 after buying an additional 772,000 shares during the period. Vanguard Group Inc. lifted its stake in shares of Kura Oncology by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 4,948,235 shares of the company's stock worth $32,658,000 after acquiring an additional 129,337 shares during the last quarter. RA Capital Management L.P. purchased a new position in Kura Oncology during the 4th quarter valued at $38,769,000. Finally, Millennium Management LLC boosted its holdings in Kura Oncology by 180.1% during the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock valued at $20,618,000 after acquiring an additional 1,521,954 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.